Altimmune, Inc. shares fall 2.17% premarket after class action lawsuit filed over IMPACT Phase 2b MASH trial.

viernes, 15 de agosto de 2025, 6:31 am ET1 min de lectura
ALT--
Altimmune, Inc. declined 2.17% in premarket trading. The company is facing legal issues as two law firms, Robbins LLP and The Gross Law Firm, have filed class action lawsuits on behalf of investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025. The lawsuits allege that Altimmune misled investors regarding the viability of its IMPACT Phase 2b MASH trial.

Altimmune, Inc. shares fall 2.17% premarket after class action lawsuit filed over IMPACT Phase 2b MASH trial.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios